2016
DOI: 10.1136/annrheumdis-2016-209247
|View full text |Cite
|
Sign up to set email alerts
|

Consensus-based recommendations for the management of juvenile dermatomyositis

Abstract: BackgroundIn 2012, a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. Juvenile dermatomyositis (JDM) is a rare disease within the group of paediatric rheumatic diseases (PRDs) and can lead to significant morbidity. Evidence-based guidelines are sparse and management is mostly based on physicians' experience. Consequently,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
111
0
6

Year Published

2017
2017
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 202 publications
(119 citation statements)
references
References 110 publications
2
111
0
6
Order By: Relevance
“…As there are few data from randomised controlled trials to guide management decisions in the children with IIM, recently several algorithms for the treatment of moderately severe JDM were developed using international expert opinion [38][39][40]. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has described several treatment strategies for initial therapy for JDM based upon a North American survey of practice [39], while recently consensus-based recommendations for the management of JDM were published by a…”
Section: International Consensus Discussion For Treatment Pathwaysmentioning
confidence: 99%
See 2 more Smart Citations
“…As there are few data from randomised controlled trials to guide management decisions in the children with IIM, recently several algorithms for the treatment of moderately severe JDM were developed using international expert opinion [38][39][40]. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) has described several treatment strategies for initial therapy for JDM based upon a North American survey of practice [39], while recently consensus-based recommendations for the management of JDM were published by a…”
Section: International Consensus Discussion For Treatment Pathwaysmentioning
confidence: 99%
“…JDM rash is known to be a photosensitive rash and sun exposure is known to exacerbate disease flares. It is thus recommended the daily use of high factor sun sunscreen [40]. Concomitant use of calcium and vitamin D supplements is recommended to prevent osteoporosis, as long term high doses of corticosteroids are usually required for the treatment of IIMs [124,125].…”
Section: Adjunctive Therapiesmentioning
confidence: 99%
See 1 more Smart Citation
“…It is important to highlight that these CTPs do not consist of therapeutic guidelines per se , but they represent arms for proposed comparative effectiveness studies, developed via consensus methodologies. Moreover, evidence-driven consensus-based recommendations for diagnosis and treatment of JDM have also been published as part of a European initiative called Single Hub and Access point for pediatric Rheumatology in Europe (SHARE) ( 67 ).…”
Section: Treatmentmentioning
confidence: 99%
“…More adverse effects were seen with ciclosporin than MTX, supporting the usual practice of corticosteroid and MTX as first line treatment ( 73 ). Intravenous immunoglobulin (IVIG) is recommended for patients with JDM refractory to steroids and methotrexate ( 67 , 68 ). An alternative DMARD suggested for severe/refractory cases of JDM or where methotrexate is not tolerated, is mycophenolate mofetil ( 67 ), beneficial for both muscle and skin disease.…”
Section: Treatmentmentioning
confidence: 99%